Q2 2024 EPS Estimates for GH Research PLC (NASDAQ:GHRS) Reduced by Analyst

GH Research PLC (NASDAQ:GHRSFree Report) – Analysts at HC Wainwright dropped their Q2 2024 earnings estimates for GH Research in a report released on Tuesday, May 7th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.22) per share for the quarter, down from their prior forecast of ($0.21). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.96) per share. HC Wainwright also issued estimates for GH Research’s FY2024 earnings at ($0.76) EPS.

A number of other equities research analysts have also recently commented on the company. JMP Securities dropped their target price on GH Research from $50.00 to $39.00 and set a “market outperform” rating on the stock in a research report on Friday, March 1st. Canaccord Genuity Group upped their target price on GH Research from $30.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday, May 6th.

Read Our Latest Stock Report on GHRS

GH Research Stock Performance

GHRS stock opened at $12.81 on Friday. The firm’s fifty day moving average is $10.74 and its 200 day moving average is $8.17. The firm has a market cap of $666.50 million, a PE ratio of -20.66 and a beta of 0.80. GH Research has a one year low of $5.05 and a one year high of $14.64.

GH Research (NASDAQ:GHRSGet Free Report) last announced its quarterly earnings results on Friday, May 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07.

Institutional Investors Weigh In On GH Research

A number of hedge funds have recently added to or reduced their stakes in GHRS. Mirae Asset Global Investments Co. Ltd. boosted its stake in GH Research by 16.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 92,784 shares of the company’s stock valued at $932,000 after acquiring an additional 12,911 shares in the last quarter. Barclays PLC lifted its stake in GH Research by 98.2% in the third quarter. Barclays PLC now owns 63,590 shares of the company’s stock valued at $640,000 after buying an additional 31,500 shares during the last quarter. PEAK6 Investments LLC boosted its holdings in shares of GH Research by 72.9% in the third quarter. PEAK6 Investments LLC now owns 40,308 shares of the company’s stock valued at $405,000 after acquiring an additional 16,991 shares during the period. Lynx1 Capital Management LP grew its position in shares of GH Research by 13.8% during the third quarter. Lynx1 Capital Management LP now owns 1,103,178 shares of the company’s stock worth $11,087,000 after acquiring an additional 133,804 shares during the last quarter. Finally, RTW Investments LP raised its position in GH Research by 53.4% in the 3rd quarter. RTW Investments LP now owns 3,327,129 shares of the company’s stock valued at $33,438,000 after purchasing an additional 1,158,172 shares during the last quarter. 56.90% of the stock is currently owned by institutional investors and hedge funds.

GH Research Company Profile

(Get Free Report)

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

Featured Stories

Earnings History and Estimates for GH Research (NASDAQ:GHRS)

Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.